Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $239.94 -2.78%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 24 | New: 62
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 24 | New: 62
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $283.00 (from $280.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $245 at UBS
- Roivant Sciences (ROIV) PT Raised to $55 at Piper Sandler
- CMS Energy (CMS) PT Lowered to $77 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
